Vemurafenib price after medical insurance

The original drug Vemurafenib (Vemurafenib) has been marketed in China and has entered the scope of Class B medical insurance, but only for BRAF determined by detection methods approved by CFDA Patients with V600 mutation-positive unresectable or metastatic melanoma are reimbursed. SpecificationsThe price of 240mg*56 tablets per box may be around 7,000 yuan. Reimbursement is different in different regions of the country, and the price after reimbursement may be different. Patients can consult at local medical insurance bureaus or hospitals.

Vemurafenib is used to treat melanoma (skin cancer) that has spread to other parts of the body or cannot be removed with surgery. Vemurafenib is also used to treat Erdheim-Chester disease, a rare blood cancer. Vemurafenib is only used if a patient's cancer has a specific genetic marker (an abnormal "BRAF" gene), and your doctor will test the patient's cancer for this gene before taking the drug. At the maximum tolerated dose of 960 mg twice daily, 31% of patients developed skin lesions that may require surgical excision. The BRIM-2 trial investigated 132 patients, and the most common adverse events were joint pain in 58% of patients, rash in 52%, and photosensitivity reactions in 52%. To better control side effects, 45% of patients required some form of dose adjustment. The median daily dose was 1750 mg, which was 91% of the maximum allowed daily dose.

The Turkish version of Vemurafenib original drug, specifications240mg*56 tablets sold overseas may cost more than 2,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively cheap. There is currently no generic version of Vemurafenib on the market. For more drug information and specific prices, please consult a medical consultant.